Robeco Institutional Asset Management B.V. Buys 34,362 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Robeco Institutional Asset Management B.V. lifted its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 17.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 226,287 shares of the biotechnology company's stock after purchasing an additional 34,362 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.50% of United Therapeutics worth $69,757,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of UTHR. Illumine Investment Management LLC lifted its stake in shares of United Therapeutics by 0.7% in the first quarter. Illumine Investment Management LLC now owns 8,604 shares of the biotechnology company's stock worth $2,652,000 after buying an additional 58 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in United Therapeutics by 31.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 9,179 shares of the biotechnology company's stock worth $2,830,000 after acquiring an additional 2,211 shares during the last quarter. State of Alaska Department of Revenue lifted its position in United Therapeutics by 0.8% in the 1st quarter. State of Alaska Department of Revenue now owns 16,692 shares of the biotechnology company's stock valued at $5,145,000 after acquiring an additional 135 shares in the last quarter. CWA Asset Management Group LLC lifted its position in United Therapeutics by 51.6% in the 1st quarter. CWA Asset Management Group LLC now owns 8,224 shares of the biotechnology company's stock valued at $2,535,000 after acquiring an additional 2,799 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC boosted its stake in United Therapeutics by 16.0% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 741 shares of the biotechnology company's stock valued at $228,000 after purchasing an additional 102 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Insiders Place Their Bets

In related news, Director Richard Giltner sold 3,036 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the sale, the director now owns 19,384 shares in the company, valued at approximately $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 12,000 shares of United Therapeutics stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the sale, the chief financial officer now owns 8,118 shares in the company, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 80,681 shares of company stock worth $24,177,219. Company insiders own 10.30% of the company's stock.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $284.09 on Friday. The stock has a market capitalization of $12.82 billion, a PE ratio of 11.34, a P/E/G ratio of 6.26 and a beta of 0.57. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82. The company's fifty day simple moving average is $301.13 and its 200-day simple moving average is $325.65.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. During the same quarter in the previous year, the company posted $6.17 earnings per share. United Therapeutics's revenue for the quarter was up 17.2% on a year-over-year basis. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. JPMorgan Chase & Co. reduced their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a report on Thursday, May 1st. HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research note on Monday, May 5th. Morgan Stanley lifted their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 1st. Finally, Cantor Fitzgerald initiated coverage on shares of United Therapeutics in a report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price objective for the company. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $393.08.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.